We found, that combining anti‐PD‐1 therapy with ACM‐peptide polymersome therapy might help overcome some of these, by more targeted immune activation and that immunisation with a combination therapy improved generation of tumour‐specific CD8+ T cells and tumour regression. Here, CD8A is linked to neoplasm.